Philips Collaborates with Accenture to Create First Proof of Concept for Delivering Vital Patient Data via Google Glass

Royal Philips ElectronicsRoyal Philips (NYSE: PHG AEX: PHIA) and Accenture (NYSE: CAN) announced the creation of a proof-of-concept demonstration that uses a Google Glass™ head-mounted display for researching ways to improve the effectiveness and efficiency of performing surgical procedures. The demonstration connects Google Glass to Philips IntelliVue Solutions and proves the concept of seamless transfer of patient vital signs into Google Glass, potentially providing clinicians with hands-free access to critical clinical information.

The new concept demonstration depicts how a clinician wearing the display could simultaneously monitor a patient's vital signs and react to surgical procedural developments without having to turn away from the patient or procedure. A clinician could also monitor a patient's vital signs remotely or enlist assistance from clinicians in other locations.

"We live in a world where being nimble is key and industry-altering ideas need to be converted to practical solutions that people can use," said Michael Mancuso, CEO, Patient Care and Clinical Informatics at Philips Healthcare. "This research explores how clinicians can achieve better access to the right information at the right time so they can focus on more efficient and effective patient care. It's a first step in researching how existing technologies can be applied to improve the quality of life of patients."

Researchers from Philips' newly created 'Digital Accelerator Lab,' a cross-sector innovation platform with labs based in the Netherlands and India, collaborated with researchers from Accenture Technology Labs to explore the potential use of Google Glass in clinical settings. The goal was to create the first proof of concept for Google Glass and Philips IntelliVue Solutions and then to begin exploring additional opportunities to integrate Google Glass seamlessly with Philips' healthcare solutions.

"Accenture's work with Philips showcases a powerful use of wearable devices in the healthcare industry, helping physicians perform their jobs more effectively and enhancing care for patients," said Paul Daugherty, chief technology officer, Accenture. "This exciting work highlights the potential of digital technologies to transform the way we work and live, and we're pleased to have collaborated with Philips to help bring this vision to life."

Aside from the possibility of operating in a hands-free environment, the Google Glass IntelliVue Solution research effort was developed to explore how to enhance a clinician's mobility by allowing the seamless transfer of patient information while on the go. Further research may indicate how to possibly enable clinicians and anesthesiologists to keep their focus on the patient while simultaneously obtaining a live view of critical patient monitoring data.

Additional topics for research may include:

  • Accessing a near real-time feed of vital signs in Google Glass;
  • Calling up images and other patient data by clinicians from anywhere in the hospital;
  • Accessing a pre-surgery safety checklist;
  • Giving clinicians the ability to view the patient in the recovery room after surgery;
  • Conducting live, first-person point-of-view videoconferences with other clinicians or medical personnel; and
  • Recording surgeries from a first-person point-of-view for training purposes.

The Philips Digital Accelerator Lab underlines Philips' commitment to developing innovative solutions across the care continuum, to improve patient outcomes, provide better value and expand access to care. Today, Philips offers a comprehensive portfolio of patient monitoring solutions ranging from bedside monitors to wearable patient monitors, combined with clinical decision support tools and mobile applications to provide immediate access to centrally held patient data. More than 190 million patients are monitored each year with Philips' patient monitors.

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people's lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2012 sales of EUR 24.8 billion and employs approximately 115,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare.

About Accenture
Accenture is a global management consulting, technology services and outsourcing company, with approximately 275,000 people serving clients in more than 120 countries. Combining unparalleled experience, comprehensive capabilities across all industries and business functions, and extensive research on the world's most successful companies, Accenture collaborates with clients to help them become high-performance businesses and governments. The company generated net revenues of US$28.6 billion for the fiscal year ended Aug. 31, 2013.

Most Popular Now

Almost All Leading AI Chatbots Show Sign…

Almost all leading large language models or "chatbots" show signs of mild cognitive impairment in tests widely used to spot early signs of dementia, finds a study in the Christmas...

New Study Reveals Why Organisations are …

The slow adoption of blockchain technology is partly driven by overhyped promises that often obscure the complex technological, organisational, and environmental challenges, according to research from the University of Surrey...

Emotional Cognition Analysis Enables Nea…

A joint research team from the University of Canberra and Kuwait College of Science and Technology has achieved groundbreaking detection of Parkinson's disease with near-perfect accuracy, simply by analyzing brain...

New Recommendations to Increase Transpar…

Patients will be better able to benefit from innovations in medical artificial intelligence (AI) if a new set of internationally-agreed recommendations are followed. A new set of recommendations published in The...

Digital Health Unveils Draft Programme f…

18 - 19 March 2025, Birmingham, UK. Digital Health has unveiled the draft programme for its Rewired 2025 event which will take place at the NEC in Birmingham in March next...

AI System Helps Doctors Identify Patient…

A new study from Vanderbilt University Medical Center shows that clinical alerts driven by artificial intelligence (AI) can help doctors identify patients at risk for suicide, potentially improving prevention efforts...

Smartphone App can Help Reduce Opioid Us…

Patients with opioid use disorder can reduce their days of opioid use and stay in treatment longer when using a smartphone app as supportive therapy in combination with medication, a...

AI's New Move: Transforming Skin Ca…

Pioneering research has unveiled a powerful new tool in the fight against skin cancer, combining cutting-edge artificial intelligence (AI) with deep learning to enhance the precision of skin lesion classification...

Leveraging AI to Assist Clinicians with …

Physical examinations are important diagnostic tools that can reveal critical insights into a patient's health, but complex conditions may be overlooked if a clinician lacks specialized training in that area...

AI can Improve Ovarian Cancer Diagnoses

A new international study led by researchers at Karolinska Institutet in Sweden shows that AI-based models can outperform human experts at identifying ovarian cancer in ultrasound images. The study is...

Major EU Project to Investigate Societal…

A new €3 million EU research project led by University College Dublin (UCD) Centre for Digital Policy will explore the benefits and risks of Artificial Intelligence (AI) from a societal...

Predicting the Progression of Autoimmune…

Autoimmune diseases, where the immune system mistakenly attacks the body's own healthy cells and tissues, often have a preclinical stage before diagnosis that’s characterized by mild symptoms or certain antibodies...